IBRANCE vs IMKELDI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. IBRANCE and IMKELDI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IBRANCE	IMKELDI
Rating	64/100	New
Pharmacy pays	—	~$25.80 /30
Type	RX	RX
Active ingredient	PALBOCICLIB	IMATINIB MESYLATE
Manufacturer	Pfizer	Shorla Oncology
Dosage forms	Capsule, Tablet	Solution
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Breast Neoplasms	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

ibrance imkeldi

Rating

64/100

New

Pharmacy pays

—

~$25.80 /30

Type

Active ingredient

PALBOCICLIB

IMATINIB MESYLATE

Manufacturer

Pfizer

Shorla Oncology

Dosage forms

Capsule, Tablet

Solution

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Breast Neoplasms

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

What is the difference between Ibrance and Imkeldi?

Ibrance contains Palbociclib, while Imkeldi contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.